Ergomed plc Share Options (7257C)

TIDMERGO

RNS Number : 7257C

Ergomed plc

19 June 2019

PRESS RELEASE

Ergomed Award of Share Options and Award of Options by Executive Chairman Over Personally Owned Shares

Guildford, UK - 19 June 2019: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that the following LTIP (Long Term Incentive Plan) awards have been made to newly-appointed CFO Richard Barfield.

The awards consist of share options over the Company's ordinary shares having a nominal value of 1 pence each (the "Options") with an exercise price of 1 pence per share. Of the total, 200,000 will vest after three years of the commencement of Richard Barfield's employment with the Company and are not subject to performance criteria. The remaining 400,000 are subject to performance criteria and vest as follows: 200,000 will vest dependent on total shareholder return of 15% per annum over three years; an additional 100,000 will vest dependent on total shareholder return of 25% per annum over three years; and an additional 100,000 will vest dependent on total shareholder return of 35% per annum over three years.

In total, 600,000 Options were granted on 18 June 2019, representing 1.3 per cent. of the issued share capital.

In addition, Dr Miroslav Reljanović, Executive Chairman of Ergomed, has granted options over 400,000 ordinary shares from his personal holding to Mr Barfield. Of the total, 100,000 will vest after three years of the commencement of Richard Barfield's employment with the Company and are not subject to performance criteria; an additional 100,000 will vest dependent on total shareholder return of 15% per annum over three years; an additional 100,000 will vest dependent on total shareholder return of 25% per annum over three years; and an additional 100,000 will vest dependent on total shareholder return of 35% per annum over three years.

The 400,000 ordinary shares over which Dr Reljanović has granted options will remain in his personal holding until exercise. Dr Reljanović is interested in 10,955,767 ordinary shares of the Company, representing 23.5 per cent. of the issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                      Dr Miroslav Reljanović 
      ----------------------------------------  ------------------------------------------------ 
 2     Reason for the notification 
      ------------------------------------------------------------------------------------------ 
 a)    Position/status                           Founder and Executive Vice-Chairman 
      ----------------------------------------  ------------------------------------------------ 
 b)    Initial notification                      Initial Notification 
        /Amendment 
      ----------------------------------------  ------------------------------------------------ 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------------------ 
 a)    Name                                      Ergomed Plc 
      ----------------------------------------  ------------------------------------------------ 
 b)    Legal Entity                              213800BVS8I9VMC1AP84 
        Identifier 
      ----------------------------------------  ------------------------------------------------ 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------------------------ 
 a)    Description of                            Ordinary shares of 1 pence each 
        the financial 
        instrument, type 
        of instrument                             GB00BN7ZCY67 
 
        Identification 
        code 
      ----------------------------------------  ------------------------------------------------ 
 b)    Nature of the                             Grant of options over a proportion of his 
        transaction                               personal shareholding. 
      ----------------------------------------  ------------------------------------------------ 
 c)    Currency                                  GBP 
      ----------------------------------------  ------------------------------------------------ 
 d)    Price(s) and                                    Price(s)                 Volume(s) 
        volume(s) 
      ----------------------------------------  ----------------------  ------------------------ 
                                 1 pence                                         400,000 
  --------------------------------------------------------------------  ------------------------ 
 
 e)    Aggregated information                    400,000 ordinary shares at an exercise price 
        - Aggregated                              of 1 pence per share. 
        volume 
        - Price 
        - Aggregated 
        total 
      ----------------------------------------  ------------------------------------------------ 
 f)    Date of the transaction                   18 June 2019 
      ----------------------------------------  ------------------------------------------------ 
 g)    Place of the                              Outside a trading venue. 
        transaction 
      ----------------------------------------  ------------------------------------------------ 
 
 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                      Richard Barfield 
      ----------------------------------------  --------------------------------------------- 
 2     Reason for the notification 
      --------------------------------------------------------------------------------------- 
 a)    Position/status                           Chief Financial Officer 
      ----------------------------------------  --------------------------------------------- 
 b)    Initial notification                      Initial Notification 
        /Amendment 
      ----------------------------------------  --------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------------------- 
 a)    Name                                      Ergomed Plc 
      ----------------------------------------  --------------------------------------------- 
 b)    Legal Entity                              213800BVS8I9VMC1AP84 
        Identifier 
      ----------------------------------------  --------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------------------------- 
 a)    Description of                            Ordinary shares of 1 pence each 
        the financial 
        instrument, type 
        of instrument                             GB00BN7ZCY67 
 
        Identification 
        code 
      ----------------------------------------  --------------------------------------------- 
 b)    Nature of the                             Grant of options under the Company's Long 
        transaction                               Term Incentive Plan 
      ----------------------------------------  --------------------------------------------- 
 c)    Currency                                  GBP 
      ----------------------------------------  --------------------------------------------- 
 d)    Price(s) and                                    Price(s)               Volume(s) 
        volume(s) 
      ----------------------------------------  ---------------------  ---------------------- 
                                1 pence                                       1,000,000 
  -------------------------------------------------------------------  ---------------------- 
 
 e)    Aggregated information                    1,000,000 ordinary shares at an exercise 
        - Aggregated                              price of 1 pence per share. 
        volume 
        - Price 
        - Aggregated 
        total 
      ----------------------------------------  --------------------------------------------- 
 f)    Date of the transaction                   18 June 2019 
      ----------------------------------------  --------------------------------------------- 
 g)    Place of the                              Outside a trading venue. 
        transaction 
      ----------------------------------------  --------------------------------------------- 
 

Enquiries:

 
 Ergomed plc                                           Tel: [phone] 
                                                                         975 
 Miroslav Reljanović (Executive Chairman) 
 
 
 Numis Securities Limited                          Tel: [phone] 
 Freddie Barnfield / Huw Jeremy (Nominated 
  Adviser) 
 James Black (Broker) 
 
 Consilium Strategic Communications - for          Tel: [phone] 
  UK enquiries 
 Chris Gardner / Mary-Jane Elliott               [e-mail] 
 Matthew Neal / Olivia Manser 
 
 MC Services - for Continental European               Tel: [phone] 
  enquiries 
 Anne Hennecke 
 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHEKLBFKQFEBBV

(END) Dow Jones Newswires

June 19, 2019 02:00 ET (06:00 GMT)